Loading...
XSTO
ACTI
Market cap14mUSD
Jul 09, Last price  
5.32SEK
1D
0.38%
1Q
8,621.31%
Jan 2017
-32.27%
Name

Active Biotech AB publ

Chart & Performance

D1W1MN
XSTO:ACTI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
51.58%
Rev. gr., 5y
-11.87%
Revenues
0k
66,359,00012,077,00053,456,00010,772,00011,356,000234,593,000219,092,000108,145,0002,265,00016,275,00019,042,00020,246,00020,051,0008,425,0006,725,00000000
Net income
-37m
L-5.33%
-139,180,000-207,718,000-181,586,000-223,977,000-221,065,000-94,550,000-175,015,000-212,086,000-231,512,000-193,531,000-59,584,000-108,793,000-36,878,000-36,066,000-32,117,000-49,883,000-58,691,000-45,800,000-39,400,000-37,300,000
CFO
-32m
L-19.80%
-100,133,000-186,704,000-159,463,000-224,772,000-196,320,000-46,971,000-240,396,000-102,250,000-267,090,000-217,887,000-73,163,000-46,447,000-40,647,000-35,813,000-32,216,000-46,166,000-54,850,000-45,741,000-40,400,000-32,400,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
URL
https://www.activebiotech.com/
IPO date
Dec 01, 1986
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT